Display options
Cite
Jimenez MA, Novelli E, Shaw GD, et al. Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease. Blood Adv. 2017;1(20):1712-1716doi: 10.1182/bloodadvances.2017006742.
Jimenez, M. A., Novelli, E., Shaw, G. D., & Sundd, P. (2017). Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease. Blood advances, 1(20), 1712-1716. https://doi.org/10.1182/bloodadvances.2017006742
Jimenez, Maritza A, et al. "Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease." Blood advances vol. 1,20 (2017): 1712-1716. doi: https://doi.org/10.1182/bloodadvances.2017006742
Jimenez MA, Novelli E, Shaw GD, Sundd P. Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease. Blood Adv. 2017 Sep 12;1(20):1712-1716. doi: 10.1182/bloodadvances.2017006742. PMID: 28966995; PMCID: PMC5617353.
Copy Download .nbib Format: NLM
Share it on

Blood Adv. 2017 Sep 12;1(20):1712-1716. doi: 10.1182/bloodadvances.2017006742.

Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease.

Blood advances

Maritza A Jimenez, Enrico Novelli, Gray D Shaw, Prithu Sundd

Affiliations

  1. Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  2. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.
  3. Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  4. Quell Pharma Inc., Half Moon Bay, CA, USA.
  5. Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

PMID: 28966995 PMCID: PMC5617353 DOI: 10.1182/bloodadvances.2017006742

[No abstract available.]

Conflict of interest statement

DISCLOSURE OF CONFLICTS OF INTEREST MAJ, PS and EN have declared that no conflict of interest exists. GDS is a Founder and holds equity in Quell Pharma Inc.

References

  1. JCI Insight. 2017 Jan 12;2(1):e89761 - PubMed
  2. Biochemistry. 2008 Apr 22;47(16):4674-82 - PubMed
  3. Lancet. 2015 Jan 10;385(9963):117-71 - PubMed
  4. J Exp Med. 2000 Jul 17;192(2):193-204 - PubMed
  5. Lancet. 2010 Dec 11;376(9757):2018-31 - PubMed
  6. Haematologica. 2014 Nov;99(11):e214-7 - PubMed
  7. J Clin Invest. 2014 Apr;124(4):1483-96 - PubMed
  8. Blood. 2009 Nov 26;114(23):4883-5 - PubMed
  9. Blood. 2016 Feb 18;127(7):801-9 - PubMed
  10. Haematologica. 2015 Oct;100(10):e390-3 - PubMed
  11. Nat Med. 2009 Apr;15(4):384-91 - PubMed
  12. Blood. 2014 Dec 11;124(25):3799-807 - PubMed
  13. PLoS One. 2015 Aug 06;10(8):e0133116 - PubMed
  14. Blood. 2015 Apr 23;125(17):2656-64 - PubMed
  15. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12 ):2392-9 - PubMed
  16. Am J Hematol. 2015 May;90(5):381-5 - PubMed
  17. Blood. 2013 Dec 5;122(24):3892-8 - PubMed
  18. N Engl J Med. 2017 Feb 2;376(5):429-439 - PubMed
  19. Blood. 2014 Jun 12;123(24):3689-90 - PubMed
  20. Blood. 2011 Mar 31;117(13):3680-3 - PubMed

Publication Types

Grant support